Table 1 Clinical and genetic variables in UBTF-TD^pos and UBTF-TD^WT patients.

Age, years, median (IQR)

57 (46–67)

41 (28–48.5)

<0.001

Sex, n (%)

 Female

2038 (49)

22 (42)

0.368

 Male

2157 (51)

30 (58)

AML type, n (%)

 de novo

3261 (78)

39 (75)

0.080

 sAML

548 (13)

11 (22)

 tAML

237 (6)

-

 HR-MDS

149 (3)

2 (3)

Laboratory, median (IQR)

 BM blasts, %

61 (38–80)

46.5 (30.5–71)

0.057

 WBC, 10⁹/L

13.3 (3–41.6)

6.3 (1.7–20)

0.128

 PLT, 10⁹/L

53 (25–98)

32 (21–50)

0.003

 Hb, g/dL

9.2 (8.0–10.6)

8.7 (7.5–9.6)

0.016

FAB subtype, n (%)

-

 M0

446 (11)

4 (8)

<0.001

 M1

846 (21)

8 (15)

 M2

1143 (28)

14 (27)

 M4

702 (17)

6 (12)

 M5

559 (14)

4 (8)

 M6

117 (3)

12 (23)

 M7

27 (1)

1 (2)

 RAEB

88 (2)

2 (3)

 RAEB-T

138 (3)

1 (2)

 n-miss

129

-

Cytogenetic risk ELN 2022, n (%)

 Favorable

322 (8)

-

0.070

 Intermediate

2802 (70)

47 (90)

 Adverse

902 (22)

3 (10)

 n-miss

169

2

 Trisomy 8

372 (9)

19 (36.5)

<0.001

NPM1^mut, n (%)

1176 (28)

-

<0.001

FLT3-ITD^pos, n (%)

872 (20.8)

26 (50)

<0.001

CEBPA^bZIP-inf, n (%)

157 (3.7)

-

<0.001